Listen, watch, read
Open an expert discussion, video or review beside the decision it explains. Start with the question, use the original publisher, then return to the lesson.
Recordings are selected from publisher descriptions, show notes and chapter lists; they have not been fully listened to or watched here. The full-text review checks are section-specific.
Listen
Podcast · EMplify · EB Medicine Wide Complex Tachycardia An ED discussion to connect a wide QRS to the patient, the differential and the next intervention.
Sam Ashoo, MD, and T. R. Eckler, MD · 27 Apr 2026 · page updated 27 May 2026 · About 50 minutes · choose a chapter
- Look or listen for
- Start with bedside steps at 7:54. For a focused return, use the accessory-pathway discussion at 14:09 or stability assessment at 27:58. Times below are the publisher’s chapter labels; seek in its player.
- Before opening
- Without naming a drug, list the findings that would make you abandon a diagnostic or infusion-first plan.
- Bring it back
- Return to the unstable-WCT case and explain what changed the treatment priority.
- Access
- Public podcast page/player and chapter list. No transcript was found on that page. The companion article/CME is subscriber material.
- Review scope
- Publisher description and chapter list checked; audio and subscriber article not reviewed.
- Boundary
- Expert discussion, not a protocol. Keep the current AHA pathway and local resuscitation policy beside it; the recording has not been auditioned here.
Publisher chapters
- 7:54 · Bedside steps
- 14:09 · AF with an accessory pathway
- 27:58 · Stable versus unstable
- 38:00 · Treatment
- 44:49 · Risk-management pitfalls
Source and access checked 2026-10-16.
Podcast · CardioNerds Acute Management of Atrial Fibrillation · episode 431 Hear how comorbid illness and ventricular function reshape the rate-versus-rhythm conversation.
Jonathan Chrispin, MD, with Naima Maqsood, Kelly Arps and Jake Roberts · 24 Oct 2025 · Case discussion · duration not confirmed
- Look or listen for
- Use the first patient in the written notes, then the decompensated-HF discussion. Compare the reason for a fast rate with the harm caused by it.
- Before opening
- In AF plus pulmonary edema, what would tell you whether the rhythm is driving instability or accompanying another illness?
- Bring it back
- Revisit the AF/decompensated-HF case. Give a recommendation, its hemodynamic boundary and a rescue plan before revealing the existing feedback.
- Access
- Public publisher player and detailed written show notes; show notes are not a verbatim transcript. No chapter times verified.
- Review scope
- Show notes checked against the lesson’s acute safety boundary; recording not auditioned.
- Boundary
- The notes’ general advice to anticoagulate before rhythm control is not a reason to delay emergency cardioversion for instability caused by AF. Use current AF/AHA guidance for cardioversion eligibility and anticoagulation.
Source and access checked 2026-10-16.
Podcast · ASHP · Clinical Conversations Atrial Fibrillation Rate vs Rhythm Debate A pharmacist-to-pharmacist debate to accompany the shift from AFFIRM-era questions to early rhythm control.
Danielle McPherson, PharmD, and Riley Wildemann, PharmD; host Vicki Basalyga, PharmD · 2021 archive · Historical debate · duration not confirmed
- Look or listen for
- Listen for which patients, treatment timing and outcomes each side is actually arguing about—not just which strategy wins.
- Before opening
- Would two trials asking about different patients and different timing necessarily give the same answer?
- Bring it back
- Return to the AFFIRM → EAST-AFNET 4 narrative. State one result you would apply and one patient to whom you would not automatically extrapolate it.
- Access
- Public publisher audio player and speaker/episode description. No transcript or chapter map verified.
- Review scope
- Publisher description and disclaimer checked; recording not auditioned.
- Boundary
- Historical context, not a current acute-care algorithm. ASHP identifies the discussion as presenter opinion, not ASHP policy or a comprehensive drug reference.
Source and access checked 2026-10-16.
Watch
Video · Ninja Nerd Antiarrhythmic Drugs Whiteboard-style cardiac physiology and drug mechanisms when a class label needs a picture behind it.
Zach Murphy · 11 Nov 2022 · 2 h 40 min · use selected chapters
- Look or listen for
- Choose one mechanism rather than the entire lecture: adenosine/digoxin at 1:01:03, sodium-channel blockers at 1:14:06, or potassium-channel blockers at 1:31:54.
- Before opening
- Sketch a nodal and a ventricular action potential. Mark where the drug you are reviewing acts.
- Bring it back
- Use the atlas to connect that target to one patient-specific hazard, interaction and monitoring finding. Check the drug-specific entry, not just its class.
- Access
- Free official YouTube lecture; creator’s notes, templates and quizzes are separate paid resources. Caption accuracy not checked.
- Review scope
- Official video description, chapter map and posted correction checked; video not watched in full.
- Boundary
- A 2022 foundational lecture, not current prescribing guidance. The creator flags a signaling correction at 1:05:28: the alpha subunit inhibits adenylyl cyclase; beta-gamma activates potassium channels.
Publisher chapters
Source and access checked 2026-10-16.
Video · CardioNerds · Cardiovascular Fundamentals The QT Interval with Dr. Nino Isakadze A visual refresher on QT measurement and its pitfalls before interpreting a proarrhythmia risk.
Nino Isakadze, MD · Publication date not confirmed · Focused lecture · duration not confirmed
- Look or listen for
- Follow the measurement explanation. Keep separate what is measured, how rate correction is chosen and what the number can tell you in this patient.
- Before opening
- Which assumptions would you check before accepting the monitor’s QTc as the final answer?
- Bring it back
- Return to the sotalol/AKI/pauses case. Explain the risk using the patient’s rhythm, exposure and electrolytes—not the QTc alone.
- Access
- Official YouTube video linked by the creator’s fundamentals page. Captions and chapter times not checked.
- Review scope
- Creator description and official video title/channel checked; recording not auditioned. Date and duration remain unverified.
- Boundary
- Measurement foundations only; do not use this older fundamentals series as the current torsades or cardioversion treatment pathway.
Source and access checked 2026-10-16.
Read
Review · EHRA / ESC · Europace Practical compendium of antiarrhythmic drugs The lead pharmacology reference: connect binding kinetics and PK to drug selection, interactions and monitoring.
Jose L. Merino, Juan Tamargo and colleagues · 2025 · correction 17 Mar 2026 · Reference-depth consensus · select a section
- Look or listen for
- Start with §§3.2–3.4 for binding/PK, then the drug’s §3.6 entry. Use §§5.1–5.3 for initiation/ECG monitoring and §5.10 for interactions. The HTML contents are easier to navigate on a phone than the full PDF.
- Before opening
- For one drug, predict how its substrate, elimination and an interacting medicine could change the ECG or toxicity risk.
- Bring it back
- Check that prediction, then work the corresponding atlas drill. Name the finding that would make you stop or choose differently.
- Access
- Open-access full HTML/PDF. Link-only here; no tables or figures reproduced.
- Review scope
- Selected mechanism, PK, monitoring and interaction sections inspected; correction identity/content checked. Not a new audit of every statement or dosing table.
- Boundary
- Expert consensus, not a randomized trial or a US product label. Read with the March 2026 correction; drug availability, initiation requirements and dosing must be reconciled with current local guidance and the specific label.
Source and access checked 2026-10-16.
Review · EHRA consensus · endorsed by HRS, APHRS and LAHRS Management of electrical storm or clustered ventricular arrhythmias For the next question after stabilization: what if VT keeps returning despite apparently successful treatment?
Radosław Lenarczyk and colleagues · Europace · 8 Apr 2024 · evidence search through Nov 2023 · Advanced optional reading · §8 acute management
- Look or listen for
- Read §8.1 on triggers and assessment, then §§8.2.3–8.2.8 on ICD management, sedation, drug therapy and escalation. Keep structural heart disease and primary electrical disease separate.
- Before opening
- A patient has recurrent ICD shocks. What might perpetuate the cycle besides failure of the antiarrhythmic drug?
- Bring it back
- Outline the ED pharmacist’s immediate work and the questions that require electrophysiology/ICU input. State where shock, sedation, hemodynamics and definitive treatment fit.
- Access
- Open-access full text. Repository access may occasionally show a browser check; the PubMed record also links the publisher.
- Review scope
- Methods and selected acute-management sections inspected, including device, sedation, pharmacotherapy and escalation. No complete dose-table audit or independent clinician approval.
- Boundary
- A consensus review, explicitly not a guideline; evidence strength varies. This adds optional context, not a new electrical-storm module. Use current AHA/local resuscitation guidance, not older regional shock/drug sequences as a US order set.
Source and access checked 2026-10-16.
Draft teaching · clinical and listening review pending
Adenosine: stop the circuit or reveal the rhythm?
The AV node can be part of the tachycardia circuit—or the route from an atrial rhythm to the ventricles. Its job changes what a brief block tells you.
Predict first
If atrial flutter continues during transient AV block, what should happen to ventricular activation? Say your prediction before changing the diagram.
Conduction intact. Compare the location of the AV node in each mechanism.
AV-node-dependent re-entry
AVNRT / typical orthodromic AVRT
The AV node participates in the circuit.
Atrial flutter
The circuit is in the atria
The AV node conducts some atrial impulses to the ventricles.
Listen to the explanation
AI narration · 1 min 21 sec. Source-checked teaching; independent clinical and listening review pending.
Use a voice from this device instead
Device read-aloud
Optional English voice from this device. Quality and availability vary. This is not the final natural narrator. The site passes only this public explanation to the device speech engine—not your notes—and makes no speech-service request. Device or operating-system handling is separate.
Device read-aloud is unavailable until a compatible English voice is found. Read the transcript below.
The explanation stops after the “Now pause” question so you can answer before continuing.
Read the transcript
Before adenosine, ask what the atrioventricular node is doing in this rhythm.
In AV nodal re-entry, and in typical orthodromic AV re-entry, nodal conduction helps sustain the circuit. Briefly interrupting that conduction can stop the tachycardia.
Atrial flutter is different. Its circuit is in the atria. The node controls how atrial impulses reach the ventricles, but it is not the engine of the flutter circuit. A transient block can slow the ventricular response and make continuing atrial activity easier to see. That is diagnostic information, not conversion of the flutter.
Now pause. If the atrial activity keeps marching through the ventricular pause, what does that tell you about the driver of the rhythm?
One important limit: termination does not prove a single diagnosis. Some atrial tachycardias also respond to adenosine. Interpret the full recorded response and the ECG, not just the final heart rate.
This mechanism lesson does not decide whether adenosine is safe for a particular patient. Instability, the rhythm pattern, contraindications, and the treatment protocol still govern the next action.
Explain the response
Synthetic teaching case. During evaluation of a stable, regular narrow-complex tachycardia, a brief AV block exposes continuing flutter waves. The ventricular rate subsequently returns.
Try a provider explanation
Explain what persisted, what changed, and why conversion was not demonstrated. Then name the patient information needed to choose the next treatment.
Compare with an example
“The atrial flutter continued while AV conduction was briefly interrupted. We have clarified the rhythm, not converted it. The next strategy depends on stability, ventricular function, symptom burden, duration and anticoagulation context, and the rest of the ECG.”
Sources and limits
Draft original teaching: source-checked by the authoring agent; separately attributed clinician review and final narrator listening review have not been completed.
Checked 2026-10-16. Original teaching synthesis, supported by AHA 2025 Adult ALS, section 17 and the rapid-bolus adenosine label. No copyrighted figures or recorded lecture audio are copied.
This focused mechanism preview is professional education, not a treatment algorithm. It does not cover administration, the full differential, or all safety exclusions. Rhythm-related instability requires the appropriate urgent pathway; irregular/polymorphic wide-complex rhythms must not be treated as the regular narrow-complex scenario shown here.